NCT02372084View on ClinicalTrials.gov

A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 21, 2015

Primary Completion Date

May 19, 2016

Study Completion Date

May 19, 2016

Conditions
Hepatic Impairment
Interventions
DRUG

osilodrostat

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33136

University of Miami / Clinical Research Services, Inc. Boynton Beach, Miami

55404

DaVita Clinical Research, Minneapolis

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY